OncologyEducation presents MedOncNow

OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast. Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.

Sequencing in Advanced Colorectal Cancer - with Dr. Scott Berry 12/23/2025

Sequencing in Advanced Colorectal Cancer - with Dr. Scott Berry In this episode, Dr. Scott Berry takes us through practical discussions on sequencing the increasing available treatment options for Advanced Colorectal cancer. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/39511755

BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin 11/24/2025

BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin As we now access Encorafenib + Cetuximab + Folfox via a Pfizer sponsored PSP for the he first line treatment Braf V600e mutated, RAS wt, dMMR/MSS metastatic Colorectal cancer, Dr. Rachel Goodwin takes us through the regimen, its practical use and efficacy and toxicity management. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/39153315

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak 10/07/2025

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/38500010

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley 09/16/2025

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/38242325

Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala 09/11/2025

Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management. This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/38180325

IPI/NIVO for mCRC with Dr. Sharlene Gill 08/21/2025

IPI/NIVO for mCRC with Dr. Sharlene Gill In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/37904365

The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth 08/11/2025

The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth In this episode of MedOncNow, Dr. Christopher Booth discusses how 3 years of a structured exercise program after adjuvant chemotherapy for resected colon cancer can improve survival. This is an affordable, accessible and evidence-based strategy that can be incorporated into practice tomorrow. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/37759995

Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa 06/02/2025

Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa In this episode of MedOncNow, Dr. Kevin Jao discusses Amivantamab + Lazertinib in the first-line treatment of EGFR-mutated NSCLC and how it fits into the treatment landscape. This is timely, as Johnson & Johnson has a time-limited access program to Ami-Laz for EGFR-mutated NSCLC, as per the Mariposa Regimen. More information in episodes 2 and 3. Proudly partnering with Oncology Education for the 2025 season. MedOncNow has been made possible by the generous unrestricted support of BMS, Eisai, Johnson and Jonhson, Merck, Pfizer and Roche Canada. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/36822770

Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2 05/16/2025

Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2 In this episode of MedOncNow, Dr. Christine Brezden-Masley explores the clinical impact of Zolbetuximab in gastric and GEJ cancers, covering patient selection, treatment integration, and implications for systemic therapy delivery. This is timely as ASTELLAS is funding both testing for Claudin 18.2 and access to Zolbetuximab for Gastric and GEJ cancers across Canada. 🎧 Catch up on Part 1 for insights into Claudin 18.2 testing and its role in guiding therapy decisions. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/36670895

Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2 05/06/2025

Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2 In this episode of MedOncNow, Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction (GEJ) and gastric cancers. He discusses key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer. This conversation is especially timely as ASTELLAS is currently funding Claudin 18.2 testing as part of the Gastric Cancer Biomarker Workflow initiative. Access to Zolbetuximab from ASTELLAS will follow in May 2025. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/36454550

Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer 03/27/2025

Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer Dr. Brandon Meyers joins Dr. Kassam to discuss the use of Adjuvant Aspirin in the management of curatively resected Colorectal Cancer in patients harbouring alterations in the PI3 Kinase pathway. This is a potentially practice-changing implementation of an affordable and tolerable drug that is easily accessible to patients. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/35888860

Resectable NSCLC: How to Choose the Right Treatment 03/03/2025

Resectable NSCLC: How to Choose the Right Treatment In episode 3 of MedOncNow, Dr. Parneet Cheema joins Dr. Kassam to discuss how to implement the multiple options available for treating resectable NSCLC. She will help us choose between CheckMate 816 and KEYNOTE-671 while also discussing CheckMate-77T, AEGEAN and IMpower010. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/35513500

2L Treatment of EGFR-Positive NSCLC 02/18/2025

2L Treatment of EGFR-Positive NSCLC Practically Speaking: Mariposa-2. In this episode of MedOncNow, Dr. Barb Melosky joins Dr. Kassam to discuss the use of Amivantimab + Carboplatin + Pemetrexed in the second-line treatment of EGFR-positive non small cell lung cancer (NSCLC) progressing after Osimertinib. A timely discussion, given that Johnson & Johnson now has a compassionate access program for this regimen. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/35344290

Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma 01/31/2025

Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma Dr. Kassam is joined by Dr. Aly-Khan Lalani to discuss the use of Belzutifan in the management of previously treated clear cell renal cell carcinoma. With Belzutifan now available in clinic, listen today for important guidance. /episode/index/show/bd87551c-e98e-4fba-819d-b06d77160772/id/35100320

OncologyEducation presents MedOncNow

TOPICS